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   To determine the effect of human lymphoblastoid interferon (HLBI) on metastatic renal cell 
carcinoma (MRCC), we performed two clinical trials. First, between 1982 and 1984, we performed 
a phase II study using 3 megaunits (MU) of HLBI daily in 25 eligible patients with MRCC. Six 
patients (24.0%) showed objective responses, including 2 with complete response (CR) and 4 with 
partial response (PR). Patients with a prior nephrectomy or with a good performance  status were 
likely to respond to the therapy. Based on the above observation, we performed a prospective 
randomized trial to compare 2 different doses of HLBI following nephrectomy. Treatment consis-
ted of HLBI, 3 MU intramuscularly 6 days a week in arm A and 1 MU intramuscularly 6 days a 
week in arm B. Treatments were started within 4 weeks after the nephrectomy and patients were 
evaluated every week for 1 month, and every month thereafter. Between 1985 and 1991, 16 patients 
were enrolled in arm A and 15 patients in arm B. Responses were seen in 5 (31.3%) of the 16 
arm A patients (4 CRs and  1 PR) and 3 (20.0%) of the 15 arm B patients (1 CR and 2 PRs). 
Most responses occurred  in patients with lung metastasis and favorable PS. There was no statis 
-tical difference in efficacy between the two arms. Hematologic toxicity was more frequent in 
arm A (43.8%) than arm B (13.3%). We conclude that further studies are needed to secure the 
clinical efficacy of HLBI for MRCC. 
                                                 (Acta Urol. Jpn. 38: 1293-1298, 1992) 














































お25例を長期経過観察 した ところ,25例中1例 を除き
全例死亡 したが,奏 効症例 の生存期間(中 間値34カ
月)は非奏効症例の生存期間(中 間値6ヵ 月)に 比べ
長い傾向が認められた.これらの症例を長期に観察 し
た結果,治 療前の脳転移症例は3例 であ ったが,死亡





























である.さ らに本臨床試験の目的 と意義 予想される
副作用を説明し.本試験について同意(informedcon-





































































































































































































































原則としてHLBIの 投与 は術後28日以内に開始 し
た.投与開始後,最 初の1ヵ 月は毎週,以 後4週毎に
患者の状態,検 査値,抗腫瘍効果を詳細に観察 した.
効果判定は投与開始後,6ヵ 月経過した時点で行い,
NC以 上の効果の認められた症例は,引 続 きHLBI


























































































































年齢,性 別とは相関を示さず,PSの 良好な症 例,





















































を対象 と して,腎 摘除術+イ ンターフェロンαとイ
ンターフェロンα単独治療 の第三相比較試験を開始
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